医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Targeted Medical Pharma Looks to China as the Next Medical Food Market

2014年05月22日 PM12:00
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Targeted Medical Pharma (OTCQB: TRGM) is currently discussing the logistics of importing the company’s medical food products into China with a large Chinese pharmaceutical company. No assurances can be made that a definitive agreement will be consummated between the two companies at this time.

“Growth of international sales and distribution will contribute to the success of our 2014 fiscal initiatives,” said William Shell, M.D., Chief Executive Officer and Chief Science Officer at Targeted Medical Pharma. “Our discussions with a Chinese firm have been positive and informative, providing our company with a pathway to registration and distribution of our products in China.”

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells and pituitary hormones, including IGF-I.

Forward-Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

CONTACT

Company Contact:
Targeted
Medical Pharma

Marcus Charuvastra, (310) 474-9809
marcusch@tmedpharma.com
or
Investor
Contact:

ProActive Capital Group
Jeff
Ramson, (646) 863-6893
ramson@proactivecapital.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent